Prophylactic anticoagulation regimens in COVID-19 and MIS-C patients. (A) Proportion of admissions receiving prophylactic anticoagulation in clinical subgroups by dose intensity (n = 208 admissions). When >1 regimen was used per admission, the regimen with either the longest duration or highest dose intensity was included. For patients with TEs, only those without TEs on admission were included (n = 14). (B) Prophylactic anticoagulation regimens in patients with COVID-19 or MIS-C (n = 220 regimens; other: rivaroxaban, apixaban, bivalirudin, warfarin, or aspirin). TE, thrombotic event; UFH, unfractionated heparin.